The role of azithromycin in healthcare-associated pneumonia treatment

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 5, 2015, Pages 517-524

  Thompson, A M ^a   Thomas, S E ^a   Schafers, S J ^a   Hartmann, A P ^a   Call, W B ^a   Bushwitz, J ^a   Deal, E N ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

adverse drug reactions; anti inflammatory effects; azithromycin; cardiotoxicity; clarithromycin; community acquired pneumonia; healthcare associated pneumonia; immunomodulatory effects; macrolides; mortality; pneumonia

Indexed keywords

AZITHROMYCIN;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; BACTEREMIA; CHLAMYDIA PNEUMONIAE; CHRONIC DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG USE; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; INFECTION RISK; LEGIONELLA PNEUMOPHILA; META ANALYSIS; MYCOPLASMA PNEUMONIAE; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION;

EID: 84941025050     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12319     Document Type: Review

References (67)

1. Bartlett JG, Mundy LM,. Community-acquired pneumonia. N Engl J Med, 1995; 333: 1618-1624.
2. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005; 171: 388-416.
3. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef M,. Health-care associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother, 2007; 51: 3568-3573.
4. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH,. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest, 2008; 134: 963-968.
5. Kollef M, Sherman G, Ward S, Fraser V,. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest, 1999; 115: 462-474.
6. Kollef M, Shorr A, Tabak Y, Gupta V, Liu L, Johannes R,. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest, 2005; 128: 3854-3862.
7. Kollef MH, Zilberberg MD, Shorr AF, Vo L, Schein J, Micek ST, Kim M,. Epidemiology, microbiology, and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect, 2011; 62: 130-135.
8. Shorr A, Zilberberg M, Hoffman J, Kan J, Kollef M, Micek S,. Azithromycin and pneumonia: outcomes in the era of healthcare-associated pneumonia. Crit Care Med, 2012; 40 (Suppl 1): 183.
9. Shorr AF, Zilberberg MD, Kan J, Hoffman J, Micek ST, Kollef MH,. Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study. BMJ Open, 2013; 3: e002898.
10. Shorr AF, Zilberberg MD, Reichley R, et al,. Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implications for hospitals. Clin Infect Dis, 2013; 57: 362-367.
11. McEvoy C, Micek ST, Reichley RM, et al,. Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia. Surg Infect (Larchmt), 2014; 15: 283-289.
12. Amsden GW,. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother, 2005; 55: 10-21.
13. Svanstrom H, Pasternak B, Hviid A,. Use of azithromycin and death from cardiovascular causes. N Engl J Med, 2013; 368: 1704-1712.
14. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM,. Azithromycin and the risk of cardiovascular death. N Engl J Med, 2012; 366: 1881-1890.
15. Brito V, Niederman MS,. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis, 2009; 22: 316-325.
16. Jeong B-H, Jeon EJ, Yoo H, et al,. Comparison of severe healthcare-associated pneumonia with severe community-acquired pneumonia. Lung, 2014; 192: 313-320.
17. Gutiérrez F, Masiá M, Mirete C, et al,. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect, 2006; 53: 166-174.
18. El-Solh AA, Sikka P, Ramadan F, Davies J,. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med, 2001; 163: 645-651.
19. Chalmers JD, Taylor JK, Singanayagam A, et al,. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis, 2011; 53: 107-113.
20. Polverino E, Dambrava P, Cilloniz C, et al,. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax, 2010; 65: 354-359.
21. Polverino E, Torres A, Menendez R, Cillõniz C, Valles JM, et al,. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. Thorax, 2013; 68: 1007-1014.
22. Seong GM, Kim M, Lee J, Lee JH, Jeong SY, Choi Y, Kim WJ,. Healthcare-associated pneumonia among hospitalized patients: is it different from community acquired pneumonia? Tuberc Respir Dis (Seoul), 2014; 76: 66-74.
23. Carratala J, Mykietiuk A, Fernandez-Sabe N, et al,. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med, 2007; 167: 1393-1399.
24. Fukuyama H, Yamashiro S, Tamaki H, Kishaba T,. A prospective comparison of nursing- and healthcare-associated pneumonia (NHCAP) with community-acquired pneumonia (CAP). J Infect Chemother, 2013; 19: 719-726.
25. Lim WS, Macfarlane JT,. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J, 2001; 18: 362-368.
26. Miyashita N, Kawai Y, Akaike H, Ouchi K, Hayashi T, Kurihara T, Okimoto N,. Clinical features and the role of atypical pathogens in nursing and healthcare-associated pneumonia (NHCAP): differences between a teaching university hospital and a community hospital. Intern Med, 2012; 51: 585-594.
27. Ma HM, Ip M, Hui E, Chan PK, Hui DS, Woo J,. Role of atypical pathogens in nursing home-acquired pneumonia. J Am Med Dir Assoc, 2013; 14: 109-113.
28. Guo H, Liu J, Collins AJ, Foley RN,. Pneumonia in incident dialysis patients-the United States Renal Data System. Nephrol Dial Transplant, 2008; 23: 680-686.
29. Nakagawa N, Saito Y, Sasaki M, Tsuda Y, Mochizuki H, Takahashi H,. Comparison of clinical profile in elderly patients with nursing and healthcare-associated pneumonia, and those with community-acquired pneumonia. Geriatr Gerontol Int, 2014; 14: 362-371.
30. Garcia-Vidal C, Viasus D, Roset A, et al,. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infect, 2011; 17: 1659-1665.
31. Maruyama T, Niederman MS, Kobayashi T, et al,. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir Med, 2008; 102: 1287-1295.
32. Slinin Y, Foley RN, Collins AJ,. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int, 2006; 70: 1135-1141.
33. Troy CJ, Peeling RW, Ellis AG, Hockin JC, Bennett DA, Murphy MR, Spika JS,. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA, 1997; 277: 1214-1218.
34. Seenivasan MH, Yu VL, Muder RL,. Legionnaires' disease in long-term care facilities: overview and proposed solutions. J Am Geriatr Soc, 2005; 53: 875-880.
35. Forgie S, Marrie TJ,. Healthcare-associated atypical pneumonia. Semin Respir Crit Care Med, 2009; 30: 67-85.
36. Altenburg J, de Graaf CS, van der Werf TS, Boersma WG,. Immunomodulatory effects of macrolide antibiotics-Part 1: Biological mechanisms. Respiration, 2011; 81: 67-74.
37. Altenburg J, de Graaf CS, van der Werf TS, Boersma WG,. Immunomodulatory effects of macrolide antibiotics-Part 2: Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration, 2011; 81: 75-87.
38. Kanoh S, Rubin BK,. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev, 2010; 23: 590-615.
39. Culic O, Erakovic V, Parnham MJ,. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharm, 2001; 429: 209-229.
40. Beigelman A, Gunsten S, Mikols C, Vidavsky I, Cannon CL, Brody SL, Walter MJ,. Azithromycin attenuates airway inflammation in a non-infectious mouse model of allergic asthma. Chest, 2009; 136: 498-506.
41. Imperi F, Leoni L, Visca P,. Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front Microbiol, 2014; 5: 178.
42. Saiman L, Marshall BC, Mayer-Hamblett N, et al,. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA, 2003; 290: 1749-1756.
43. Yamada K, Yanagihara K, Kaku N, et al,. Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, 2013; 57: 3883-3888.
44. Hoffman N, Lee B, Hentzer M, et al,. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic Pseudomonas aeruginosa lung infection in cftr-/- mice. Antimicrob Agents Chemother, 2007; 51: 3677-3687.
45. Culic O, Erakovic V, Cepelak I, et al,. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharm, 2002; 450: 277-289.
46. Spagnolo P, Fabbri LM, Bush A,. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J, 2013; 42: 239-251.
47. Albert RK, Connett J, Bailey WC, et al,. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011; 365: 689-698.
48. Walkey A, Wiener RS,. Macrolide antibiotics and survival in patients with acute lung injury. Chest, 2012; 141: 1153-1159.
49. Laserna E, Sibila O, Fernandez JF, et al,. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia. Chest, 2014; 145: 1114-1120.
50. Said MA, Johnson HL, Nonyane BAS, Deloria-Knoll M, O'Brien KL, et al,. Estimating the burden of Pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE, 2013; 8: e60273.
51. Bordon J, Peyrani R, Brock GN, Blasi F, Rello J, File T, et al,. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia. Chest, 2008; 133: 618-624.
52. Mufson MA, Stanek RJ,. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med, 1999; 107: 34S-43S.
53. Martinez JA, Horcajada JP, Almela M, et al,. Addition of a macrolide to a B-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis, 2003; 36: 389-395.
54. Dwyer R, Ortqvist A, Aufwerber E, et al,. Addition of a macrolide to a beta-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis, 2006; 25: 518-521.
55. Waterer GW, Somes GW, Wunderink RG,. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med, 2001; 161: 1837-1842.
56. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR,. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis, 2012; 55: 371-380.
57. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, Iga T,. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother, 2000; 44: 2630-2637.
58. Howard PA,. Azithromycin-induced proarrhythmia and cardiovascular death. Ann Pharmacother, 2013; 47: 1547-1551.
59. Samarendra P, Kumari S, Evan SJ, Sacchi TJ, Navarro V,. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol, 2001; 24: 1572-1574.
60. Matsunaga N, Oki Y, Prigollini A,. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J, 2003; 116: U666.
61. Kim MH, Berkowitz C, Trohman RG,. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol, 2005; 28: 1221-1222.
62. Huang BH, Wu CH, Hsia CP, Chen CY,. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol, 2007; 30: 1579-1582.
63. Russo V, Puzio G, Siniscalchi N,. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed, 2006; 77: 30-32.
64. Strle F, Maraspin V,. Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr, 2002; 114: 396-399.
65. Rao GA, Mann JR, Shoaibi A, et al,. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med, 2014; 12: 121-127.
66. Food and Drug Administration. FDA drug safety communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. March 12, 2013. http://www.fda.gov/drugs/drugsafety/ucm341822.htm (accessed 18 March 2013).
67. Food and Drug Administration. FDA statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. May 17, 2012. http://www.fda.gov/Drugs/Drugsafety/ucm304372.htm (accessed 14 August 2014).